Chairs: Sagar Lonial, Mohamad Mohty, Antonio Palumbo
SESSION I: BIOLOGY
Cytogenetics and NGS – Hervé Avet-Loiseau
SNP, mutations and GEP – Pieter Sonneveld
Minimal residual disease – Bruno Paiva
Bone disease – Nicola Giuliani
SESSION II: BIOLOGY
Clonality – Nikhil Munshi
Immunity – Fabio Malavasi
Signalling pathways – Tuna Mutis
SESSION III: MYELOMA DIAGNOSIS AND STAGING (INCLUDING MGUS AND SMM)
When to treat – Sonja Zweegman
Imaging – Elena Zamagni
MGUS and smoldering myeloma – Maria-Victoria Mateos
Special lecture:
Drug development in myeloma – Sagar Lonial
SESSION IV: TREATMENT OF TRANSPLANT ELIGIBLE PATIENTS
Induction – Hermann Einsele
Consolidation – Michele Cavo
Allogeneic transplantation – Nicolaus Kröger
SESSION V: TREATMENT OF ELDERLY PATIENTS
Front line therapy for fit patients – Mohamad Mohty
Front line therapy for frail patients – Alessandra Larocca
Supportive care – Heinz Ludwig
SESSION VI: SPECIAL LECTURE
Cost-effectiveness analysis to inform health technology assessment considerations in haematological oncology – Andrea Manca
SESSION VII: TREATMENT OF RELAPSED PATIENTS
IMids – Jens Hillengass
Proteasome inhibitors – Thierry Facon
Monoclonal antibodies – Torben Plesner
How to sequence agents in RRMM – Philippe Moreau
SESSION VIII: AMYLOIDOSIS AND WALDENSTRÖM MACROGLOBULINEMIA
Waldenström – Steven Treon
Amyloidosis – Giampaolo Merlini